Artiva Biotherapeutics, Inc.
ARTV · NASDAQ
Market closed$9.76$0.720000 (+7.96%)After hours $9.79 · +0.31%
Key statistics
Previous close$9.04
Open$8.89
Day high$10.12
Day low$8.75
52-week high$14.53
52-week low$2.22
Market cap241.24M
Volume359.70K
Average volume595.37K
P/E ratio-2.76
Forward P/E—
EPS-3.54
Dividend yield0.00%
Market context
Why it moved
Artiva Biotherapeutics (ARTV) surged today after the company announced new employee inducement grants of 288,800 RSUs for 17 new hires, signaling accelerated hiring and expansion momentum that investors interpreted as a bullish sign of the clinical-stage biotech's growing workforce and pipeline confidence.
What is happening
Recent company-specific developments and publisher coverage.
Investing.com · July 14, 2026Ra Capital Management funds buy $194k in Artiva Biotherapeutics stockGlobeNewswire · June 8, 2026Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodaySimply Wall Street · May 21, 2026Have Insiders Sold Artiva Biotherapeutics Shares Recently?Investing.com · May 8, 2026Artiva Biotherapeutics stock surges on positive trial dataGlobeNewswire · May 8, 2026Artiva Biotherapeutics Announces Pricing of $300 MillionGlobeNewswire · May 8, 2026Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business HighlightsSimply Wall Street · October 21, 2025Artiva Biotherapeutics (ARTV) Is Up 71.1% After FDA Fast Track Win for Novel Arthritis Therapy – What's ChangedInvestorideas.com · October 17, 2025Biotech Stock Artiva Biotherapeutics (Nasdaq: ARTV) Soars on News FDA has granted Fast Track Designation to AlloNK Benzinga · June 8, 2026Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target Mt Newswire · June 8, 2026Artiva Biotherapeutics Reports Positive AlloNK Data Across Autoimmune Diseases at EULAR 2026 Benzinga · June 8, 2026Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate Benzinga · May 19, 2026Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6 Mt Newswire · May 19, 2026Artiva Biotherapeutics Appoints Diego Miralles as President Benzinga · May 12, 2026Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41 Benzinga · May 11, 2026Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40 Benzinga · May 11, 2026Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40